Alaunos Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.1231
- Today's High:
- $0.1275
- Open Price:
- $0.1275
- 52W Low:
- $0.12
- 52W High:
- $3.73
- Prev. Close:
- $0.12
- Volume:
- 534174
Company Statistics
- Market Cap.:
- $34.60 million
- Book Value:
- 0.09
- Revenue TTM:
- $2.93 million
- Operating Margin TTM:
- -1099.9%
- Gross Profit TTM:
- $-19596000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -39.5%
- Return on Equity TTM:
- -119.14%
Company Profile
Alaunos Therapeutics Inc had its IPO on 2005-08-24 under the ticker symbol TCRT.
The company operates in the Healthcare sector and Biotechnology industry. Alaunos Therapeutics Inc has a staff strength of 34 employees.
Stock update
Shares of Alaunos Therapeutics Inc opened at $0.13 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.12 - $0.13, and closed at $0.12.
This is a +3.17% increase from the previous day's closing price.
A total volume of 534,174 shares were traded at the close of the day’s session.
In the last one week, shares of Alaunos Therapeutics Inc have slipped by -11.57%.
Alaunos Therapeutics Inc's Key Ratios
Alaunos Therapeutics Inc has a market cap of $34.60 million, indicating a price to book ratio of 5.0196 and a price to sales ratio of 50.8406.
In the last 12-months Alaunos Therapeutics Inc’s revenue was $2.93 million with a gross profit of $-19596000 and an EBITDA of $-29403000. The EBITDA ratio measures Alaunos Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Alaunos Therapeutics Inc’s operating margin was -1099.9% while its return on assets stood at -39.5% with a return of equity of -119.14%.
In Q2, Alaunos Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 631.4%.
Alaunos Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alaunos Therapeutics Inc’s profitability.
Alaunos Therapeutics Inc stock is trading at a EV to sales ratio of 51.1619 and a EV to EBITDA ratio of -4.3055. Its price to sales ratio in the trailing 12-months stood at 50.8406.
Alaunos Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $27.93 million
- Total Liabilities
- $5.05 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $135000
- Dividend Payout Ratio
- 0%
Alaunos Therapeutics Inc ended 2024 with $27.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $27.93 million while shareholder equity stood at $21.65 million.
Alaunos Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $5.05 million in other current liabilities, 241000.00 in common stock, $-899448000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.32 million and cash and short-term investments were $18.32 million. The company’s total short-term debt was $339,000 while long-term debt stood at $0.
Alaunos Therapeutics Inc’s total current assets stands at $18.78 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $4000.00 compared to accounts payable of $1.48 million and inventory worth $0.
In 2024, Alaunos Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $135000.
Comparatively, Alaunos Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.12
- 52-Week High
- $3.73
- 52-Week Low
- $0.12
- Analyst Target Price
- $1.75
Alaunos Therapeutics Inc stock is currently trading at $0.12 per share. It touched a 52-week high of $3.73 and a 52-week low of $3.73. Analysts tracking the stock have a 12-month average target price of $1.75.
Its 50-day moving average was $0.33 and 200-day moving average was $0.53 The short ratio stood at 17.81 indicating a short percent outstanding of 0%.
Around 886.4% of the company’s stock are held by insiders while 2987.3% are held by institutions.
Frequently Asked Questions About Alaunos Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.